Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of New Oral Semaglutide Formulations in Healthy Males
NCT03638778Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2018
- Primary completion
- Dec 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration time curve from 0 to 24 hours. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03638778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638778.